Bli medlem
Bli medlem

Du är här


Novartis International AG: Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology

Novartis International AG / Novartis continues to grow immuno-oncology
pipeline through collaboration andlicensing agreement with Surface Oncology .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
* Agreement gives Novartis access to four pre-clinical programs that target
regulatory T cell populations, inhibitory cytokines, and immunosuppressive
metabolites in the tumor microenvironment
* Novartis diverse immuno-oncology portfolio already includes seven
additional programs in clinical trials and five more expected to enter the
clinic by the end of 2016

Basel, January 11, 2016
Novartis announced today that it is adding to its diverse and deep
immuno-oncology pipeline through a strategic alliance and licensing agreement
with Surface Oncology. The agreement gives Novartis access to four
pre-clinical programs that target regulatory T cell populations, inhibitory
cytokines, and immunosuppressive metabolites in the tumor microenvironment.
These programs will be explored as monotherapies and in combination with
other complementary therapies in Novartis' immuno-oncology and targeted
therapy portfolios.

"We have several programs now in the clinic that aggressively address the
complexities of the tumor microenvironment," said Mark Fishman, President of
the Novartis Institutes for BioMedical Research. "This alliance with Surface
Oncology is another building block in our strategy to develop a portfolio of
programs that we believe will lead the next wave of immuno-oncology

At the start of 2015 Novartis launched a new immuno-oncology research team led
by cancer vaccine pioneer Glenn Dranoff. In a short period of time, this team
has rapidly built a broad portfolio of clinical and pre-clinical programs
focused on stimulating the body's immune system to combat cancers through
targeting critical regulatory steps in the anti-tumor immune response. Today
the company's immuno-oncology portfolio includes novel checkpoint inhibitors,
chimeric antigen receptor T-cell (CART) technology, myeloid cell targeting
agents, the T cell stimulating factor IL-15, STING agonists that enhance
immune recognition of cancers, and adenosine receptor antagonists and
TGF-beta blocking antibodies that overcome immunosuppression in the tumor

Seven of these candidates are already in clinical trials and five more are
expected to enter the clinic individually and as combinations by the end of
2016. Novartis' myeloid cell targeting program (MCS110), anti-TIM-3 program
(MGB453), IL-15-agonist (NIZ985) checkpoint inhibitors targeting PD-1
(PDR001) and LAG-3 (LAG525), and a small molecule adenosine receptor
antagonist (NIR178) are now in phase 1 clinical trials. The CART program
(CTL019) is in phase 2 clinical trials. A STING agonist (MIW815), a GITR
agonist, and an anti-TGF-beta antibody are progressing toward first-in-human
clinical trials in 2016.

This rich immuno-oncology pipeline together with a deep targeted therapy
portfolio provides Novartis with the opportunity to attack cancer in powerful
and complementary ways: through enhancing immune-mediated tumor destruction
and promoting direct tumor cell killing. Together, these synergistic
approaches may accomplish more durable clinical benefits for a larger
proportion of cancer patients.


The foregoing release contains forward-looking statements that can be
identified by words such as "continues," "pipeline," "expected," "will,"
"building block," "strategy," "believe," "next wave," "launched,"
"candidates," "progressing," "may," or similar terms, or by express or
implied discussions regarding potential marketing approvals for the four
pre-clinical programs included in the alliance with Surface Oncology, MCS110,
MGB453, NIZ985, PDR001, LAG525, NIR178, CTL019, MIW815, and the other
clinical and pre-clinical candidates in the Novartis immuno-oncology
pipeline, or regarding potential future revenues from such product
candidates. You should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and expectations
of management regarding future events, and are subject to significant known
and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that any of the four
pre-clinical programs subject to the alliance with Surface Oncology, MCS110,
MGB453, NIZ985, PDR001, LAG525, NIR178, CTL019, MIW815, or the other clinical
and pre-clinical candidates in the Novartis immuno-oncology pipeline will be
submitted or approved for sale in any market, or at any particular time. Nor
can there be any guarantee that such product candidates will be commercially
successful in the future. In particular, management's expectations regarding
the Novartis immuno-oncology pipeline could be affected by, among other
things, the uncertainties inherent in research and development, including
unexpected clinical trial results and additional analysis of existing
clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; unexpected safety issues; unexpected manufacturing or quality
issues, and other risks and factors referred to in Novartis AG's current Form
20-F on file with the US Securities and Exchange Commission. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained
in this press release as a result of new information, future events or

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2014, the Group
achieved net sales of USD 58.0 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 120,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visit

Novartis is on Twitter. Sign up to follow @Novartis

# # #

Novartis Media Relations

| Central media line : |
|+41 61 324 2200 |
| Eric Althoff Jeff Lockwood |
| |
|Novartis Global Media Relations Novartis Institutes for BioMedical Research |
|+41 61 324 7999 (direct) +1 617 871 7026 (direct) |
|+41 79 593 4202 (mobile) +1 617 510 6997 (mobile) |
| |

For Novartis multimedia content, please

For questions about the site or required registration, please

Novartis Investor Relations

| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.